Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CPHINASDAQ:GRTXNASDAQ:MYNZNASDAQ:TRAW On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPHIChina Pharma$1.63-3.0%$7.12$1.20▼$3.35$5.32M0.8564,530 shs43,803 shsGRTXGalera Therapeutics$0.03+2.0%$0.03$0.02▼$0.15$1.95M1.77103,537 shs5,001 shsMYNZMainz Biomed$1.99-2.5%$2.85$1.92▼$35.60$6.85M0.5129,550 shs65,929 shsTRAWTraws Pharma$1.87+31.7%$1.64$0.97▼$19.44$10.41M1.59709,204 shs62.53 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPHIChina Pharma+5.00%-24.32%-12.04%-91.68%-94.32%GRTXGalera Therapeutics+8.09%+4.53%+5.83%-33.51%-88.19%MYNZMainz Biomed+1.24%-2.86%-28.42%-58.79%-94.13%TRAWTraws Pharma+2.90%+8.40%0.00%-40.59%+141,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCPHIChina PharmaN/AN/AN/AN/AN/AN/AN/AN/AGRTXGalera Therapeutics0.2553 of 5 stars0.03.00.00.00.61.70.0MYNZMainz Biomed3.2034 of 5 stars3.35.00.00.03.00.81.3TRAWTraws Pharma0.6562 of 5 stars0.03.00.00.02.20.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPHIChina Pharma 0.00N/AN/AN/AGRTXGalera Therapeutics 0.00N/AN/AN/AMYNZMainz Biomed 2.50Moderate Buy$14.00603.52% UpsideTRAWTraws Pharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPHIChina Pharma$4.30M1.24N/AN/A$0.70 per share2.33GRTXGalera TherapeuticsN/AN/AN/AN/A($2.41) per shareN/AMYNZMainz Biomed$893.99K7.66N/AN/A$10.82 per share0.18TRAWTraws Pharma$227K45.84N/AN/A$12.70 per share0.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPHIChina Pharma-$3.08MN/A0.00∞N/A-85.56%-63.93%-31.42%N/AGRTXGalera Therapeutics-$59.08M-$0.35N/A∞N/AN/AN/A-99.34%8/12/2025 (Estimated)MYNZMainz Biomed-$26.30M-$65.60N/AN/AN/AN/AN/AN/A7/1/2025 (Estimated)TRAWTraws Pharma-$18.95M-$32.81N/AN/AN/A-62,294.25%N/A-822.38%8/13/2025 (Estimated)Latest GRTX, TRAW, CPHI, and MYNZ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/1/2025N/AMYNZMainz Biomed-$2.80N/AN/AN/AN/AN/A5/15/2025Q1 2025TRAWTraws Pharma-$8.04$2.09+$10.13$2.09$0.06 million$0.06 million3/31/2025Q4 2024 & Study UpdateTRAWTraws Pharma-$7.00$95.66+$102.66$95.66$0.06 million$0.06 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCPHIChina PharmaN/AN/AN/AN/AN/AGRTXGalera TherapeuticsN/AN/AN/AN/AN/AMYNZMainz BiomedN/AN/AN/AN/AN/ATRAWTraws PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPHIChina Pharma0.220.790.26GRTXGalera TherapeuticsN/A9.749.74MYNZMainz BiomedN/A0.240.19TRAWTraws PharmaN/A1.071.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPHIChina PharmaN/AGRTXGalera Therapeutics50.77%MYNZMainz BiomedN/ATRAWTraws Pharma7.95%Insider OwnershipCompanyInsider OwnershipCPHIChina Pharma17.32%GRTXGalera Therapeutics12.90%MYNZMainz Biomed18.20%TRAWTraws Pharma13.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPHIChina Pharma2503.26 million15.92 millionNot OptionableGRTXGalera Therapeutics3075.46 million47.38 millionOptionableMYNZMainz Biomed303.44 million1.64 millionNot OptionableTRAWTraws Pharma175.56 million3.15 millionOptionableGRTX, TRAW, CPHI, and MYNZ HeadlinesRecent News About These CompaniesTraws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug RigosertibJune 3 at 7:00 AM | globenewswire.comTraws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic PreparednessMay 27, 2025 | globenewswire.comTraws Pharma Unveils New Strategic Antiviral FocusMay 19, 2025 | tipranks.comTraws Pharma Highlights Q1 2025 Financial Progress and Antiviral DevelopmentsMay 18, 2025 | msn.comTraws Pharma Reports First Quarter 2025 Results and Business HighlightsMay 15, 2025 | globenewswire.comTraws Pharma Appoints New Chairman Amid Leadership ChangesApril 18, 2025 | tipranks.comThe Escalator: HHS, Spectrum Science, Alvotech and moreApril 3, 2025 | mmm-online.comTraws Pharma Reports 2024 Financial Results and Advances Bird Flu and COVID ProgramsApril 2, 2025 | msn.comTraws Pharma reports FY24 EPS ($35.21)April 1, 2025 | markets.businessinsider.comTraws Pharma, Inc. (TRAW) Virtual Investor Event TranscriptApril 1, 2025 | seekingalpha.comTraws Pharma, Inc.: Traws Pharma Reports Full Year 2024 Results and Business HighlightsMarch 31, 2025 | finanznachrichten.deTraws Pharma Reports Full Year 2024 Results and Business HighlightsMarch 31, 2025 | markets.businessinsider.comTraws Pharma Announces CEO Transition as Werner Cautreels RetiresMarch 30, 2025 | msn.comTraws Pharma, Inc.: Traws Pharma Announces Management UpdatesMarch 29, 2025 | finanznachrichten.deTraws Pharma: Werner Cautreels to Retire as CEO, While Continuing as a Bd Member >TRAWMarch 29, 2025 | marketwatch.comTraws Pharma: Werner Cautreels to Retire as CEO, While Continuing as a Bd Member >TRAWMarch 29, 2025 | marketwatch.comTraws Pharma Announces Virtual Investor Event to Showcase Innovative Treatments for Bird Flu and COVID-19March 29, 2025 | msn.comTraws Pharma CEO Werner Cautreels retires, Iain Dukes named interim CEOMarch 29, 2025 | markets.businessinsider.comTraws Pharma Announces Management UpdatesMarch 28, 2025 | globenewswire.comTraws Pharma Announces Promising Data for Ratutrelvir as a COVID-19 TreatmentMarch 27, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGRTX, TRAW, CPHI, and MYNZ Company DescriptionsChina Pharma NYSE:CPHI$1.63 -0.05 (-2.98%) Closing price 03:59 PM EasternExtended Trading$1.66 +0.03 (+1.90%) As of 04:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.Galera Therapeutics NASDAQ:GRTX$0.03 +0.00 (+1.97%) As of 01:21 PM EasternGalera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.Mainz Biomed NASDAQ:MYNZ$1.99 -0.05 (-2.45%) Closing price 04:00 PM EasternExtended Trading$2.03 +0.04 (+2.01%) As of 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.Traws Pharma NASDAQ:TRAW$1.87 +0.45 (+31.69%) Closing price 04:00 PM EasternExtended Trading$1.88 +0.01 (+0.53%) As of 05:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Reasons Amazon Could Be the Best Tech Performer in June Ollie’s Q1 Earnings: The Good, the Bad, and What’s Next Applied Digital: CoreWeave’s AI Deal Lights a $7 Billion Fuse Qualcomm: A Technical Deep-Dive Confirms the Worst Rocket Lab Expands Into Payloads: Should You Be Paying Attention? Steel Dynamics Shares Climb After Tariff Announcement Palantir Soars on Government Deals as Valuation Debate Lingers Broadcom Earnings Preview: AVGO Stock Near Record Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
